![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ARTANN LABS, PROUROCARE TO BENEFIT FROM $3 MILLION DEVELOPMENT GRANT
ARTANN LABS, PROUROCARE TO BENEFIT FROM $3 MILLION DEVELOPMENT GRANT
The National Cancer Institute has awarded a three-year Small Business Innovation Research Phase II Competitive Renewal grant of up to $3 million to Artann Laboratories, according to the firm's development partner, vision and sensing technology firm ProUroCare Medical.
The grant will be used to help develop the ProUroScan, a mechanical prostate imaging system to diagnose and screen for prostate cancer, ProUroCare said Oct. 5.
The ProUroScan is designed as a "portable cost-effective device that mimics a digital rectal examination of the prostate," the firm said. Electronically stored images can also be used to monitor changes in the prostate over time, the firm said.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct